A University of Alberta research team published preclinical data in Cell Biomaterials on D-GK17, a human-derived antimicrobial peptide that targets bacterial and fungal biofilms. Biofilms are the sticky extracellular matrix bacterial and fungal communities create that render traditional antibiotic treatments substantially less effective; biofilm-associated infections drive a major portion of antimicrobial resistance and hospital-acquired infection burden. D-GK17 demonstrated stability, non-toxicity to human cells, and broad-spectrum activity against multidrug-resistant pathogens in the preclinical work. The team is filing a patent through the University of Alberta and developing gel and bandage delivery formulations for skin infections and cancer-treatment-related mouth ulcers (chemotherapy and radiation-induced oral mucositis is a substantial unmet-need indication in oncology). D-GK17 extends the rapidly-growing antimicrobial peptide therapeutic category, which the FDA PCAC February 2027 docket also advances via the cathelicidin (LL-37) peptide review. The AMP category is under active development across marine-derived (shrimp SALF-based), computational (MAC-AMP AI design system), and human-derived platforms, with cross-cutting applications spanning antimicrobial resistance, cancer therapy, and antiviral therapy.
Holland & Knight and Mondaq legal analyses published following the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) vote clarify the rulemaking process for the six recommended peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; Emideltide/DSIP rejected). Key legal clarifications: PCAC recommendations are advisory only; HHS Secretary Robert F. Kennedy Jr. must formally approve the substances for Section 503A Bulks List inclusion; no compounding pharmacy is permitted to legally compound the peptides until final rulemaking completes; formal rulemaking typically takes 12-24 months from advisory-committee recommendation (Notice of Proposed Rulemaking, public comment period, response to comments, final rule with effective date). Even after final rule takes effect, individual states retain authority under state pharmacy board oversight to further restrict or condition compounded-peptide preparation. Separately, the FDA has announced a second PCAC peptide meeting before the end of February 2027 to review five additional peptides: cathelicidin (LL-37, antimicrobial peptide), GHK-Cu (copper tripeptide cosmetic peptide), dihexa acetate (nootropic), melanotan II (α-MSH analog), and pegylated mechano growth factor (PEG-MGF, muscle repair). Combined, the July 2026 and February 2027 PCAC dockets bring 12 peptides through advisory-committee review as part of the broader Trump administration and HHS Secretary RFK Jr. peptide deregulation agenda that has moved through the regulatory system since Q1 2026.
The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides for Section 503A Bulks List inclusion. The February 2027 docket covers: cathelicidin (LL-37), a broad-spectrum antimicrobial peptide with anti-infective and immune-modulatory activity; GHK-Cu (glycyl-histidyl-lysine copper tripeptide), a widely-marketed cosmetic and wound-healing peptide previously in FDA Category 2; dihexa acetate, an angiotensin IV-derived nootropic that has been marketed for cognitive enhancement; melanotan II, an alpha-melanocyte-stimulating hormone analog marketed for skin pigmentation (self-tanning) and appetite suppression; and pegylated mechano growth factor (PEG-MGF), a muscle-repair peptide derived from insulin-like growth factor 1 splice variants. The February 2027 review continues the July 23-24, 2026 PCAC session that recommended 6 of 7 peptides for Section 503A Bulks List inclusion (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon approved; Emideltide/DSIP rejected). FDA has not yet posted the final date and public-comment docket details for the February 2027 meeting. Under standard rulemaking timelines, the FDA's process of Notice of Proposed Rulemaking, public comment period, and final rule after any positive PCAC recommendation takes 12-24 months.